18-51047178-A-G

Variant summary

Our verdict is Benign. The variant received -8 ACMG points: 2P and 10B. PM2BP4_StrongBP6BP7BS1

The NM_005359.6(SMAD4):​c.132A>G​(p.Val44Val) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000197 in 152,260 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. V44V) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)

Consequence

SMAD4
NM_005359.6 synonymous

Scores

2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:6

Conservation

PhyloP100: -0.0820

Publications

0 publications found
Variant links:
Genes affected
SMAD4 (HGNC:6770): (SMAD family member 4) This gene encodes a member of the Smad family of signal transduction proteins. Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The protein acts as a tumor suppressor and inhibits epithelial cell proliferation. It may also have an inhibitory effect on tumors by reducing angiogenesis and increasing blood vessel hyperpermeability. The encoded protein is a crucial component of the bone morphogenetic protein signaling pathway. The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome. [provided by RefSeq, May 2022]
SMAD4 Gene-Disease associations (from GenCC):
  • juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Genomics England PanelApp, G2P, PanelApp Australia
  • Myhre syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, G2P, Labcorp Genetics (formerly Invitae)
  • generalized juvenile polyposis/juvenile polyposis coli
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp
  • juvenile polyposis syndrome
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • familial thoracic aortic aneurysm and aortic dissection
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary hemorrhagic telangiectasia
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • pulmonary arterial hypertension
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -8 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.55).
BP6
Variant 18-51047178-A-G is Benign according to our data. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652. Variant chr18-51047178-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 382652.
BP7
Synonymous conserved (PhyloP=-0.082 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0000197 (3/152260) while in subpopulation AFR AF = 0.0000723 (3/41480). AF 95% confidence interval is 0.0000192. There are 0 homozygotes in GnomAd4. There are 1 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SMAD4NM_005359.6 linkc.132A>G p.Val44Val synonymous_variant Exon 2 of 12 ENST00000342988.8 NP_005350.1 Q13485A0A024R274

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SMAD4ENST00000342988.8 linkc.132A>G p.Val44Val synonymous_variant Exon 2 of 12 5 NM_005359.6 ENSP00000341551.3 Q13485
ENSG00000267699ENST00000590722.2 linkn.*155A>G non_coding_transcript_exon_variant Exon 3 of 9 2 ENSP00000465737.1 E7EUB6
ENSG00000267699ENST00000590722.2 linkn.*155A>G 3_prime_UTR_variant Exon 3 of 9 2 ENSP00000465737.1 E7EUB6

Frequencies

GnomAD3 genomes
AF:
0.0000197
AC:
3
AN:
152260
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000723
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD4 exome
Cov.:
32
GnomAD4 genome
AF:
0.0000197
AC:
3
AN:
152260
Hom.:
0
Cov.:
32
AF XY:
0.0000134
AC XY:
1
AN XY:
74396
show subpopulations
African (AFR)
AF:
0.0000723
AC:
3
AN:
41480
American (AMR)
AF:
0.00
AC:
0
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5200
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10632
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68032
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.542
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000151

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:6
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Jun 30, 2016
Color Diagnostics, LLC DBA Color Health
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 30, 2022
Sema4, Sema4
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome Benign:2
Mar 18, 2025
Myriad Genetics, Inc.
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. -

Jun 08, 2023
All of Us Research Program, National Institutes of Health
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:1
Apr 19, 2021
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Benign:1
Jun 06, 2018
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Juvenile polyposis syndrome Benign:1
Jan 23, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.55
CADD
Benign
6.9
DANN
Benign
0.67
PhyloP100
-0.082
PromoterAI
0.0048
Neutral

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs965942065; hg19: chr18-48573548; API